Related Experiment Video
Updated: Jul 19, 2026

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
Published on: July 30, 2009
Clinical experience with remimazolam in pediatric anesthesiology: An educational focused review
Joseph D Tobias1,2,3
1Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
Abstract:
Remimazolam is a novel ultrashort-acting benzodiazepine, which like midazolam, results in sedation, anxiolysis, and amnesia through its agonistic effects on the gamma-amino butyric acid A receptor. As opposed to midazolam, its unique metabolism is via tissue esterases, which results in a rapid elimination with a limited context sensitive half-life and prompt dissipation of its effect when administration is discontinued. Remimazolam received FDA approval for use in adults in 2020. In preliminary and initial clinical trials, its efficacy and safety has been suggested in the adult population, both as a primary agent for procedural sedation or as an adjunct to general anesthesia. There are limited data regarding the use of remimazolam in infants and children and its use in this population remains off label as it does not hold FDA-approval in pediatric-aged patients. This narrative outlines the pharmacologic properties of this unique medication, reviews previous published reports of its role in pediatric-aged patients, and discusses dosing parameters and clinical use in this population.
Insights
Remimazolam, an ultrashort-acting benzodiazepine, offers rapid sedation and recovery via tissue esterase metabolism. Its use in pediatric patients is under investigation, with limited data currently available for this off-label application.
Area of Science:
- Pharmacology
- Anesthesiology
Background:
- Remimazolam is a novel, ultrashort-acting benzodiazepine approved for adult procedural sedation and anesthesia.
- Unlike midazolam, remimazolam is metabolized by tissue esterases, leading to rapid elimination and quick recovery.
- Limited data exists on remimazolam's efficacy and safety in pediatric populations.
Purpose of the Study:
- To outline the pharmacologic properties of remimazolam.
- To review existing literature on remimazolam use in pediatric patients.
- To discuss dosing and clinical application of remimazolam in children.
Main Methods:
- Pharmacological profile review.
- Literature search for pediatric case reports and clinical trials.
- Analysis of published dosing parameters and clinical outcomes.
Main Results:
- Remimazolam exhibits rapid onset and offset of action due to esterase metabolism.
- Preliminary adult data suggest efficacy and safety for procedural sedation and anesthesia.
- Published pediatric data are scarce, highlighting a gap in knowledge.
Conclusions:
- Remimazolam's unique pharmacokinetic profile is advantageous for procedural sedation.
- Further research is warranted to establish safety and efficacy in pediatric patients.
- Off-label use in children requires careful consideration and monitoring.
Related Concept Videos
Parenteral Anesthetics: Overview
Inhalational Anesthetics: Overview
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
REM Sleep Behavior Disorder
RBD is significantly associated with...

